BioLineRx Ltd.

(BLRX) Trade

By |

Profile

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.

Contact Information

Website: www.biolinerx.com
Email: IR@biolinerx.com
Main Phone: +972 86429100
Address: 2 HaMa'ayan Street
City / Town: Modi'in
Country: ISR
Postal Code: 7177871

Issuer Information

Exchange: NSC
CEO: Philip Serlin
Employees: 42

Equities News

Profile

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.

Contact Information

Website: www.biolinerx.com
Email: IR@biolinerx.com
Main Phone: +972 86429100
Address: 2 HaMa'ayan Street
City / Town: Modi'in
Country: ISR
Postal Code: 7177871

Issuer Information

Exchange: NSC
CEO: Philip Serlin
Employees: 42

Equities News

$ 1.74 $ 0.02 (1.16%)
Last Price 1.74 Change $ 0.02 Change % 1.16 Tick N/A
Bid 1.72 Bid Size 13,700.00 Ask 1.78 Ask Size 2,700.00
Open 1.75 High 1.75 Low 1.72 Prev Close 1.72
Last Trade Volume 218,830 52 Wk Hi 4.75 52 Wk Low 1.07
Market Cap 34.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 19,765,216.00 EPS (TTM) -0.21 PE Ratio N/A Exchange NCM
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 4 4 4 4
Low Target Price Estimate 2 2 2 2
Mean Target Price Estimate 3 3 3 3
Standard Deviation 1 1 1 1
Date of Most Recent Estimate 04/05/18 04/05/18 04/05/18 04/05/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1